When Vertex Pharmaceuticals' Incivek generated more than $1 billion in sales in its first nine months on the market a few years ago, the pharmaceutical industry was put on notice that hepatitis C might just be a source of both major innovation and major sales. But even so, the performance of Gilead Sciences' hep C portfolio during a 19-month period was several miles beyond unprecedented. From the launch of Sovaldi in December 2013 through the end of the second quarter of 2015, that drug and its follow-on Harvoni brought Gilead about $22 billion in sales, with Sovaldi setting a first-year record of more than $10 billion in 2014 and Harvoni tracking to easily break that and set a record for the highest annual revenue for any prescription product ever in 2015.
Along the way, Gilead's financials have been transformed – the company's revenue more than doubled while net income nearly quadrupled in 2014 —and the decision to acquire Pharmasset back in 2011 for $11 billion, considered expensive and risky by many analysts back then, has been amply justified. By the end of the second quarter of 2015 Gilead was sitting on nearly $15 billion in liquidity, nearly six times what the company had at the beginning of the Sovaldi adventure at the end of 2013, putting it in an excellent position for M&A activity.
And the competition has quite literally been wiped right off the market, with Vertex withdrawing Incivek in October 2014 and sales of J&J's Olysio suffering a drop of more than 85 percent after the launch of Harvoni. On top of this, Gilead continues to make strides in its traditional wheelhouse of HIV, with Complera/Eviplera and Stribild moving past the billion-dollar mark for the first time with annual growth of more than 50 percent each and several other combination products awaiting FDA approval. Faced with all that, the editors of Med Ad News had little trouble naming Gilead as the magazine's Company of the Year.
In spite of all these records, though, Gilead executives remain focused on the science.
Gilead's top-line revenue for 2014 was $24.89 billion, an improvement of 122 percent (!) over the previous year. Net income nearly quadrupled, from $3.08 billion to $12.1 billion. Diluted EPS more than quadrupled, from $1.81 to $7.35. R&D spending rose 34.6 percent for 2014, to $2.85 billion. In the first half of 2015, the company's top line rose 37.3 percent to $15.84 billion. Net income increased 50 percent year-over-year to $8.83 billion. Diluted EPS grew from $3.52 during first-half 2014 to $5.68. R&D expenditure improved from $1.18 billion to $1.51 billion during the first six months of 2015. Gilead executives are projecting full-year 2015 revenue at between $29 billion and $30 billion.
The product line that would change the face of both Gilead and hepatitis C treatment was first acquired by the company when it purchased Pharmasset in November 2011 for the then-considered-steep price of $11 billion, a nearly 90 percent premium on Pharmasset's market value at the time. Inspiring this kingly investment was the compound at the top of Pharmasset's pipeline, then known as PSI-7977, which had recently been advanced into Phase III trials. That compound was later named sofosbuvir, and given the trade name Sovaldi when approved by FDA in December 2013.
Practically from the moment of its approval, Sovaldi was breaking revenue records. The product was approved on December 6; by the end of the year it had already earned $139 million in sales. In its first full quarter on the market, Q1 of 2014, it became a blockbuster more than twice over, with $2.27 billion in sales. And by the end of 2014, Sovaldi had rolled up a total of $10.28 billion in sales for the year, by several orders of magnitude the greatest for any first-year drug ever, and No. 2 among all drugs for the year, behind only Humira. In fact, Sovaldi's 2014 sales were less than $1 billion short of matching the entire revenue generated by Gilead during 2013.
Sovaldi's reign at the top of Gilead's portfolio would be brief, though. In October 2014, FDA approved Harvoni (ledipasvir 90 milligrams/sofosbuvir 400 milligrams), the first once-daily single tablet regimen for the treatment of chronic hepatitis C genotype 1 infection in adults. Harvoni combines the NS5A inhibitor ledipasvir with Sovaldi. Harvoni's efficacy has been established in patients with chronic hepatitis C virus (HCV) genotype 1 infection, with a treatment duration of eight, 12, or 24 weeks depending on prior treatment history, cirrhosis status, and baseline viral load. Eight weeks of treatment with Harvoni can be considered for treatment-naïve patients without cirrhosis who have baseline HCV viral load below 6 million IU/mL. The U.S. marketing clearance was followed by approvals in Europe during November and Japan during July.
Harvoni's FDA approval was supported by data from three Phase III studies, ION-1, ION-2, and ION-3. These studies evaluated eight, 12, or 24 weeks of treatment with Harvoni, with or without ribavirin, among nearly 2,000 genotype 1 HCV patients with compensated liver disease. The studies included non-cirrhotic treatment-naïve patients (ION-3), cirrhotic and non-cirrhotic treatment-naïve patients (ION-1), and cirrhotic and non-cirrhotic patients who failed prior therapy with an interferon-based regimen, including regimens containing an HCV protease inhibitor (ION-2). The primary endpoint for each study was sustained virologic response (HCV undetectable) 12 weeks after completing therapy (SVR12). Patients who achieve SVR12 are considered cured of HCV. In these studies, ribavirin was not shown to increase response rates. Trial participants in the ribavirin-free arms achieved SVR12 rates of 94 to 99 percent.
That work has been paying off rapidly. In the final quarter of 2014, its very first on the market, Harvoni generated $2.18 billion in sales. In the first half of 2015 the medicine brought in an extraordinary $7.19 billion in sales, putting it on pace to pass Sovaldi's 2014 performance and set a record for highest annual brand revenue generated in industry history, with Lipitor producing about $13.7 billion between marketers Pfizer and Astellas Pharma in 2006. And even after being pushed out of the spotlight by its follow-on, Sovaldi still generated $2.26 billion in sales for the first half of 2015, meaning that Sovaldi-containing products were responsible for $9.45 billion in sales in the first half of the year alone.
More may be coming. In April, Gilead announced preclinical data and results from Phase I and Phase II studies supporting the development of an investigational all-oral, pan-genotypic regimen of Sovaldi, the investigational NS5A inhibitor GS-5816, and GS-9857, an investigational NS3/4A protease inhibitor.
In preclinical studies, GS-9857 demonstrated similarly potent antiviral activity against HCV replicons of all tested genotypes (1-6), as well as an improved resistance profile compared to other HCV protease inhibitors. In a healthy volunteer study, GS-9857 showed a favorable pharmacokinetic profile. Data from a three-day monotherapy study also demonstrated that GS-9857 was well-tolerated and achieved median HCV RNA reductions of more than 3 log10 IU/mL for HCV patients with genotypes 1, 2, 3, and 4 at the 100 milligram dose.
A Phase II study of triple-combination therapy with a fixed-dose combo of SOF/GS-5816 plus GS-9857 among genotype 1 patients showed sustained virologic response (SVR12) rates following six weeks of treatment of 93 percent among treatment-naïve, non-cirrhotic patients, 87 percent among treatment-naïve, cirrhotic patients, and 67 percent among those who had failed therapy with two or more direct-acting antiviral agents. The four-week regimen resulted in a sub-optimal SVR12 rate of 27 percent.
In September 2014, Gilead signed non-exclusive licensing agreements with seven India-based generic pharmaceutical manufacturers to expand access to its chronic hepatitis C medicines in developing countries. The agreements allow the companies – Cadila Healthcare Ltd., Cipla Ltd., Hetero Labs Ltd., Mylan Laboratories Ltd., Ranbaxy Laboratories Ltd., Sequent Scientific Ltd., and Strides Arcolab Ltd. – to manufacture Sovaldi and Harvoni for distribution in 91 developing countries.
The countries within the agreement account for more than 100 million people living with hepatitis C, representing 54 percent of the total global infected population. In January, the company expanded these agreements to include the investigational NS5A inhibitor GS-5816, which is being evaluated in Phase III clinical studies as part of a single tablet regimen that combines the drug compound and Sovaldi for the treatment of all six genotypes of hepatitis C.
Under the licensing agreements, the Indian companies receive a complete technology transfer of the Gilead manufacturing process to enable them to scale up production as quickly as possible. The licensees also set their own prices for the generic product they produce, paying a royalty on sales to Gilead to support product registrations, medical education and training, safety monitoring and other essential business activities. The licenses also permit the manufacture of Sovaldi or Harvoni in combination with other chronic hepatitis C medicines.
In December, Gilead announced an expansion to its agreement with Janssen R&D Ireland for the development and commercialization of a new once-daily single tablet regimen containing Gilead's tenofovir alafenamide (TAF) and emtricitabine, and Janssen's rilpivirine. The original agreement was established in 2009 for the development and commercialization of Complera – marketed as Eviplera in the European Union – which combines tenofovir disoproxil fumarate, emtricitabine, and rilpivirine in a once-daily tablet. Gilead will initiate Phase III studies of emtricitabine/rilpivirine/TAF in the coming months. Pending the product's approval, Gilead will be responsible for the manufacturing, registration, distribution, and commercialization of the regimen in most countries, while Janssen will distribute in approximately 17 markets. TAF is a novel nucleotide reverse transcriptase inhibitor that has demonstrated high antiviral efficacy at a dose 10 times lower than Gilead's Viread, as well as an improved renal and bone safety profile.
Gilead and Janssen also amended a licensing agreement for the development and commercialization of a once-daily single tablet regimen for HIV containing Gilead's TAF, emtricitabine, and cobicistat, and Janssen's darunavir. Under the amended agreement, Janssen is responsible for further development of the regimen and, subject to regulatory approval, the manufacturing, registration, distribution, and commercialization of the product worldwide.
Also in December, Gilead and Ono Pharmaceutical Group entered into an exclusive license agreement for the development and commercialization of ONO-4059, Ono's oral Bruton's tyrosine kinase (BTK) inhibitor for the treatment of B-cell malignancies and other diseases. Under the terms of the agreement, Gilead provided Ono with an upfront payment plus additional payments based upon achievement of certain development, regulatory, and commercial milestones. The companies are collaborating jointly on global development of ONO-4059. Gilead has exclusive rights to develop and commercialize ONO-4059 in all countries of the world outside of Japan, South Korea, Taiwan, China, and the Association of Southeast Asian Nations (ASEAN) countries, where Ono retains development and commercialization rights.
ONO-4059 is a selective, once-daily, oral inhibitor of BTK, which has been shown to play a role in the survival and proliferation of malignant B-cells. Ono has presented preliminary Phase I data showing clinical activity in chronic lymphocytic leukemia and non-Hodgkin lymphoma at several scientific conferences. Ono and Gilead plan to develop ONO-4059 for the treatment of B-cell malignancies and other diseases as a monotherapy and in combination with approved and investigational agents, including combinations with kinase inhibitors in Gilead's portfolio.
In January, Gilead signed a definitive deal to acquire Phenex Pharmaceuticals AG's Farnesoid X Receptor (FXR) program comprising small molecule FXR agonists for treating liver diseases including nonalcoholic steatohepatitis (NASH). Under the terms of the agreement, Gilead provided Phenex with an upfront payment plus additional payments based upon achievement of certain development milestones that may potentially be worth up to $470 million.
NASH is a common, serious chronic liver disease characterized by inflammation and excessive fat accumulation in the liver and may lead to progressive fibrosis, cirrhosis, and liver failure. NASH is estimated to affect 10 to 20 percent of people in the developed world. There are currently no approved therapies to treat NASH. FXR is a nuclear hormone receptor that regulates bile acid, lipid and glucose homeostasis, which can help reduce liver steatosis and inflammation, and may help prevent liver fibrosis.
In May, Gilead signed a definitive agreement to acquire EpiTherapeutics ApS for $65 million, subject to certain purchase price adjustments, to be financed through available cash on hand. EpiTherapeutics has generated a library of first-in-class, selective small molecule inhibitors of epigenetic regulation of gene transcription, in particular histone demethylases. The company's lead pre-clinical compounds are being studied for the treatment of certain cancers.
After Sovaldi, Gilead's top-selling brand in 2014 was the HIV combination product Atripla, which generated $3.47 billion in sales, down 4.9 percent from the previous year. According to company leaders, this was mostly due to competition with other brands in the Gilead HIV portfolio, particularly Complera/Eviplera and Stribild. In first-half 2015, Atripla sales fell another 8.1 percent to $1.52 billion. Atripla is a combination of efavirenz, emtricitabine, and tenofovir.
Next up in leading 2014 sales was the HIV drug Truvada, a combination of tenofovir disoproxil fumarate and emtricitabine. Truvada sales for the year totaled $3.34 billion, an improvement of 6.5 percent over 2013. Gilead executives credited this growth to an increase in selling prices and sales volume growth in the United States. In the first half of 2015, Truvada sales edged up another 3.4 percent to $1.62 billion.
Another combination HIV product –the emtricitabine/rilpivirine/tenofovir combination Complera/Eviplera – was fifth among Gilead products in 2014, crossing the blockbuster barrier for the first time by growing 51.6 percent to $1.23 billion. Company leaders say this growth was due to sales volume growth in the United States and Europe. In first-half 2015, Complera/Eviplera sales rose another 24.9 percent to $687 million.
Next up was yet another combination HIV therapy that grew even faster than Complera – the elvitegravir/cobicistat/emtricitabine/tenofovir combination product Stribild. Sales of Stribild more than doubled in 2014, from $539 million to $1.2 billion, again because of sales volume increases in the United States and Europe. In the first half of 2015, Stribild sales nearly improved to $803 million from $485 million in the one-year-earlier period. According to company executives, more than 70 percent of newly diagnosed HIV patients in the United States are now prescribed a Gilead single tablet regimen such as Atripla, Truvada, Complera, or Stribild.
The fifth-ranked sales generator of Gilead's HIV blockbusters, Viread, generated sales of $1.06 billion in 2014, an improvement of 10.3 percent. In the first half of 2015, Viread sales rose another 7 percent to $505 million.
Moving outside HIV, sales of the pulmonary arterial hypertension product Letairis grew 14.4 percent to $595 million in 2014. In first-half 2015, Letairis sales rose 22 percent to $327 million.
The angina product Ranexa generated sales of $510 million in 2014, an improvement of 13.6 percent. In the first half of 2015, the product's sales were up another 10.3 percent to $258 million.
In July 2014, FDA approved Zydelig (idelalisib) 150 milligram tablets for the treatment of three B-cell blood cancers. Zydelig is indicated in combination with rituximab for patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy and as monotherapy for patients with relapsed follicular B-cell non-Hodgkin lymphoma (FL) and small lymphocytic lymphoma (SLL) who have received at least two prior systemic therapies. Accelerated approval was granted for FL and SLL based on overall response rate. Zydelig is a first-in-class inhibitor of PI3K delta, a protein that is over-expressed in many B-cell malignancies and plays a role in the viability, proliferation and migration of these cancer cells.
The product's approval in CLL is supported primarily by data from a randomized, placebo-controlled Phase III trial of Zydelig plus rituximab in 220 patients with relapsed CLL who were not able to tolerate standard chemotherapy. The study was stopped early in October 2013 by an independent Data Monitoring Committee due to a highly statistically significant benefit in progression-free survival in the Zydelig arm as compared to those receiving rituximab alone. Median PFS was not reached in the Zydelig plus rituximab arm and was 5.5 months in the placebo plus rituximab arm. FDA granted Zydelig a Breakthrough Therapy designation for relapsed CLL.
Zydelig's accelerated approval in FL and SLL, two types of indolent non-Hodgkin lymphoma, were supported by data from a single-arm Phase II study of Zydelig monotherapy in patients refractory to rituximab and alkylating-agent-containing chemotherapy. In the study, Zydelig achieved an overall response rate of 54 percent and 58 percent, respectively, in FL and SLL patients. Of the responses seen in FL patients, 8 percent were complete responses; all 15 responses in SLL patients were partial responses. The median duration of response was 11.9 months in SLL patients and median duration of response was not reached in FL patients. Improvement in patient survival or disease related symptoms has not been established in these indications.
In September 2014, Gilead announced results from the AMBITION study, a randomized, double-blind, multicenter study of first-line combination therapy with Letairis and tadalafil in patients with pulmonary arterial hypertension, which was conducted in collaboration with GlaxoSmithKline. In AMBITION, first-line treatment of pulmonary arterial hypertension with the combination of Leitairis 10 milligrams and tadalafil 40 milligrams reduced the risk of clinical failure by 50 percent compared to the pooled Leitairis and tadalafil monotherapy arm. The combination was also statistically significant versus the individual Leitairis and tadalafil monotherapy groups for the primary endpoint. Rates of serious adverse events and events leading to discontinuation were similar across treatment arms. Gilead submitted the AMBITION data in a supplemental new drug application to FDA in December 2014.
Leitairis, a selective endothelin type-A receptor antagonist, and tadalafil, a PDE5 inhibitor, are each approved in the United States, the European Union, and other countries as once-daily treatments for PAH (WHO Group 1), in patients with WHO/NYHA functional class II and III symptoms. Leitairis is indicated in the United States to improve exercise ability and delay clinical worsening and in the EU to improve exercise capacity. Tadalafil, which is marketed as Adcirca, is indicated in the United States and the EU to improve exercise ability and capacity, respectively. Preclinical data have suggested these therapies may have synergistic effects.
Also in September, Gilead announced results from a Phase II study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2 (LOXL2), in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer. In the study, the addition of simtuzumab (200 milligrams or 700 milligrams) to gemcitabine did not significantly increase progression-free survival compared to placebo plus gemcitabine. PFS was the primary endpoint of the study.
In this randomized, double-blind, placebo-controlled Phase II trial, 236 patients with advanced pancreatic cancer received intravenous gemcitabine plus either intravenous simtuzumab or placebo in cycles of 28 days. Median PFS for the simtuzumab 200 milligrams, simtuzumab 700 milligrams, and placebo groups was 3.5 months, 3.7 months, and 3.7 months, respectively. The difference in PFS between the simtuzumab and placebo arms was not statistically significant.
"Although simtuzumab did not provide clinical benefit in difficult-to-treat advanced pancreatic cancer patients in this study, we continue to explore simtuzumab in other areas of unmet medical need, with ongoing clinical trials in colorectal cancer, myelofibrosis, and serious fibrotic lung and liver diseases," Dr. Bischofberger says.
The investigational monoclonal antibody simtuzumab is highly selective for LOXL2, an enzyme that modifies the extracellular matrix by promoting the cross-linking of collagen fibers. LOXL2 is thought to play an important role in tumor progression and metastasis and in the development of fibrotic diseases. Simtuzumab is being evaluated in several Phase II trials, including in combination with FOLFIRI for advanced colorectal cancer, in combination with ruxolitinib for myelofibrosis, as monotherapy for the rare lung disease idiopathic pulmonary fibrosis, and for liver fibrosis caused by non-alcoholic steatohepatitis and primary sclerosing cholangitis.
In November, Gilead filed an NDA to FDA for an investigational, once-daily single tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (TAF) (E/C/F/TAF) for treating HIV-1 infection in adults. The data submitted in the NDA support use of the regimen among adult and adolescent treatment-naïve HIV individuals, virologically suppressed patients who switch regimens and those with renal impairment. If approved, E/C/F/TAF would be Gilead's first single tablet regimen to contain TAF.
The NDA for E/C/F/TAF is supported by 48-week data from two pivotal Phase III studies in which the regimen met its primary objective of non-inferiority compared to Gilead's Stribild (elvitegravir 150 milligrams/cobicistat 150 milligrams/emtricitabine 200 milligrams/tenofovir disoproxil fumarate 300 milligrams) among treatment-naïve patients. In the studies, E/C/F/TAF demonstrated improved renal and bone safety compared to Stribild. The NDA is also supported by data from additional Phase III studies evaluating the TAF-based regimen among virologically suppressed patients who switched to E/C/F/TAF and among patients with renal impairment.
In April, Gilead submitted an NDA to FDA for two doses of an investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF) for the treatment of HIV-1 infection in adults and pediatric patients age 12 years and older, in combination with other HIV antiretroviral agents.
The F/TAF NDA is supported by data from Phase III clinical studies evaluating the safety and efficacy of E/C/F/TAF for the treatment of HIV-1 infection among treatment-naïve adults, in which the F/TAF-based regimen (administered as E/C/F/TAF) resulted in non-inferior efficacy and improved renal and bone laboratory parameters as compared to F/TDF-based therapy (administered as E/C/F/TDF or Stribild). The NDA is also supported by data from additional Phase III studies evaluating the F/TAF-based regimen (administered as E/C/F/TAF) among treatment-naïve adolescents, virologically suppressed adults who switched regimens and adults with mild-to-moderate renal impairment. Also, bioequivalence studies demonstrated that the formulation of the fixed-dose combinations of F/TAF achieved the same drug levels in the blood as in E/C/F/TAF.
In July, Gilead filed an NDA to FDA for an investigational, once-daily single tablet regimen combining emtricitabine and tenofovir alafenamide (TAF) with rilpivirine (R/F/TAF) from Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, for treating HIV-1 infection in adult and pediatric patients 12 years of age and older. The data submitted in the NDA support the use of R/F/TAF among patients who are HIV treatment-naïve or who are virologically suppressed and want to replace their current antiretroviral treatment regimen.


text:
Henry Perigal Borrell (1795, London – 2 October 1851, Smyrna) was a British numismatist.  He was the son of John Henry Borrell (anglicised from Borel), a London clockmaker from Couvet, and Kitty Borrell (née Howe).  Having learned the numismatics trade in London, he traveled to the Ottoman Empire and set up home and shop in Smyrna as a trader, from 1818 right up until his death.  Two years after his arrival, in 1820, he married Emelia Boddington in Smyrna.  In the 1820s, he obtained an inscription from Aphrodisias, a copy of which he sent to August Boeckh.  In 1838 he met the 6th Duke of Devonshire at Smyrna and sold him the Chatsworth Head (found at Tamassos).  Via the Bank of England, Borrell also supplied coins to the British Museum.

He also devoted much time and energy to discovering unpublished ancient Greek coins, with his results being presented in papers in the Revue Numismatique, the Numismatic Chronicle (including articles in 1839 on "Coins in Andeda in Pisida" and in 1841 "On the coins reading OKOKLIEŌN"), and a number of German numismatic periodicals.  In 1836 he published at Paris a "Notice sur quelques médailles grecques des rois de Chypre" (Notice on some Greek medals of the kings of Cyprus) in Paris.  He also became an associate member of the Numismatic Society of London on 28 November 1839, and remained so until his death.  His coins, antiquities, and gems collection was sold after his death by Sotheby and Wilkinson of London in 1851, who also sold his numismatic library 2 years later, on 28 February 1853.  Most of his many children remained in Smyrna, though Frederick Anthony Borrell (1836–1905) returned to London, marrying Laura Bithinia Maceroni there in 1857.
Henry had sent a notebook of more than 200 ancient Greek and other Eastern Mediterranean inscriptions to James Kennedy Baillie MRIA, Rector of Ardtrea (1793–1864) during his lifetime, and it still survives today.

Family
Henry Perigal Borrell had 6 siblings: Harriot Borrell, Elizabeth Borrell, Judith Catherine Borrell, Ann Magdalene Borrell, Maximilian John Borrell and George Howe Borrell.

Descendants
Henry Perigal Borrell and his wife have a few notable descendants.

 Miles Malleson
 Junio Valerio Borghese

Notes

Other sources
Gentleman's Magazine, 2nd ser., 39 (1853), 324
Notice of his death in "Proceedings of the Numismatic Society for 24 June 1852", Numismatic Chronicle, 14 (1851–2)
List of honorary members in R. A. G. Carson and H. Pagan, A history of the Royal Numismatic Society, 1836–1986 (1986), 79
F.Boase, Modern English biography: containing many thousand concise memoirs of persons who have died since the year 1850, 6 vols. (privately printed, Truro, 1892–1921); repr.(1965)
 "Inscriptions of Aphrodisias Project"

1795 births
1851 deaths
English numismatists

redpajama_set_name: RedPajamaWikipedia


text:
Top of the page.
Skip the menu to main contents.
Move to main menu.
Skip to main contents.
Help Menu starts here.
Skip the Help menu to Search Within Site Feature.
Search Within Site Feature starts here.
Skip the Search Within Site Feature to main menu.
Skip the Help menu to main menu.
Main menu starts here.
Skip the main menu to current location in your website.
Current location in your website.
What's New>
FUJIFILM Toyama Chemical enters agreement with Appili Therapeutics regarding the assignment of rights for the development and marketing of T-2307, a candidate compound for the treatment of fungal diseases.
Start main contents.
The information in news releases is current at the time of the release. Note that the information shown here may not be latest information (termination of production or sales, changes to specifications or pricing, organizational or contact address changes, etc.), and may be subject to change without prior notice.
FUJIFILM Toyama Chemical Co., Ltd.
Tokyo, November 21, 2019 ― FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada) announced today it has entered an agreement with Appili Therapeutics ("Appili") regarding the assignment of rights for the development and marketing of T-2307 outside of Japan. Subject to terms of the agreement, FUJIFILM Toyama Chemical will transfer the development and marketing rights of the compound to Appili and receive milestones payments as well as royalties in the future.
T-2307, an antifungal candidate compound developed by FUJIFILM Toyama Chemical, exhibits it's antifungal activity through a novel mode of action whereby it actively accumulates in fungal cells*1 and is designed to selectively disrupt the function of fungal mitochondria*2.
In the course of R&D with primary focus of targeting fungi, FUJIFILM Toyama Chemical has discovered and developed T-2307 for the treatment of various mycoses*3 including those due to drug resistant strains. The company continued to conduct clinical development of T-2307, including Phase I clinical trials in the United States.
Appili established in 2015 in Canada, is engaged in the R&D of drugs specializing in the area of infectious diseases. The company was listed in July 2019 on the Toronto Stock Exchange, and has been accelerating the development of new drugs. Through conclusion of this agreement, Appili plans to carry out a Phase II clinical trial of T-2307 targeting cryptococcal meningitis*4, a disease for which an effective treatment drug is being sought.
FUJIFILM Toyama Chemical has been promoting the R&D of treatment drugs with unique mode of action, focusing on "infectious diseases" as one of the key areas.
The agreement will contribute to solving social issues through the provision of innovative and high value-added drugs through the cooperation of Appili and FUJIFILM Toyama Chemical and also would widen the physician's choice by treating fungal infections as well as the treatment options of the patient.
* 1	Microorganisms called "mold" or "yeast". The majority of funguses is harmless to healthy individuals, but may cause mycoses in immunocompromised conditions.
* 2	Organelles found in most eukaryotic cells. Mitochondria are membrane-bound cell organelles that generate most of the chemical energy needed to power the cell's biochemical reactions.
* 3	An infection caused by a fungus that enters deep areas of the body such as the lungs, liver and the brain. It is a type of opportunistic infection, caused by pathogens that do not occur in healthy individuals, but develop in patients whose immune system has declined because of immunocompromised condition in case of bone marrow or organ transplants, long term administration of steroids and/or HIV/AIDS. It is caused by fungus species such as Candida, Aspergillus, and Cryptococcus.
* 4	Cerebral meningitis caused by Cryptococcus species. Under immunocompromised conditions, cryptococcal fungal cells that penetrate from the respiratory organs through the blood stream and enter the cerebrospinal fluid, causing inflammation of the membranes covering the spinal cord and brain. In August 2018, the U.S. FDA added cryptococcal meningitis as a tropical infectious disease requiring the development of treatment drugs, and established a program to promote drug development (Priority Review Voucher: The right to guarantee priority review at the time of filing applications for approval).
About FUJIFILM Toyama Chemical
FUJIFILM Toyama Chemical was launched by merging FUJIFILM RI Pharma Co., Ltd., a company that conducts research, development, manufacture, and sales of radiopharmaceuticals, and TOYAMA CHEMICAL CO., LTD., a company that conducts research, development, manufacture, and sales of small molecule pharmaceutical products. FUJIFILM Toyama Chemical dedicates efforts to developing innovative diagnostic and therapeutic radiopharmaceuticals and therapeutic drugs with unique action mechanisms in the fields of "oncology", "central nervous system diseases", and "infectious diseases" where significant unmet medical needs still exist, under close collaboration with FUJIFILM Corporation, which focuses on research of new medicines. The joining of FUJIFILM Toyama Chemical's and Fujifilm' know-how will also advance the development of new medicines utilizing drug delivery system (DDS) technologies that deliver the required amount of a drug in a timely manner to a specific body area. Also, by exploring synergy with in vitro diagnostic (IVD) devices and reagents owned by Fujifilm group companies, the company will expand its offering of comprehensive solutions from "diagnosis" to "treatment".
For more information of FUJIFILM Toyama Chemical, please visit http://fftc.fujifilm.co.jp/en/
About Appili Therapeutics
Appili Therapeutics Inc. was founded to advance the global fight against infectious disease by matching clearly defined patient needs with drug development programs that provide solutions to existing challenges patients, doctors, and society face in this challenging disease space. Appili has built a pipeline of assets designed to address a broad range of significant unmet medical needs in the infectious disease landscape. This diverse pipeline aims to address some of the most urgent threats in global public health. Via an in-licensing program, Appili acquired the rights to ATI-1701, a vaccine for tularemia, that it is developing to mitigate the risks of a very serious biological weapons threat. ATI-1503 is a drug discovery program aimed at generating negamycin analogue candidates, which are a novel class of antibiotics with broad-spectrum activity against Gram-negative superbugs. ATI-1501 employs Appili's proprietary, taste-masked, oral-suspension technology with metronidazole for the growing number of patients with difficulty swallowing. Headquartered in Halifax, Nova Scotia, with offices in Mississauga, Ontario, Appili is pursuing worldwide opportunities in collaboration with science and industry commercial partners, governments and government agencies. For more information, visit www.AppiliTherapeutics.com.
Latest What's New
2018 What's New
Footer starts here.
©FUJIFILM Toyama Chemical Co., Ltd.
Pages ends here.
Move to top of the page.

redpajama_set_name: RedPajamaCommonCrawl


text:
"Having no expectations has served us rather well": DiS meets Alvvays
by Dom Gourlay September 15th, 2015
Last summer, Canadian five-piece Alvvays emerged out of nowhere with arguably the definitive song of 2014 - 'Archie Marry Me'. Their self-titled debut LP followed soon after and since then, they've spent the ensuing twelve months on a tour that doesn't finish until December of this year.
Currently midway through the UK leg of the tour, the five-piece - Molly Rankin (vocals, guitar), Alec O'Hanley (guitar), Kerri MacLennan (keyboards), Brian Murphy (bass) and Phil MacIsaac (drums) - have firmly established themselves as one of the most vibrant live acts on the circuit.
Later this evening, they'll delight several hundred punters at Nottingham's Rescue Rooms. Before all that, Rankin and O'Hanley have kindly agreed to give DiS a very candid thirty minutes of their time.
Here's what they had to say...
DiS: You've been touring on and off for the best part of a year and played numerous festivals in the process. What have been your most memorable and enjoyable experiences?
Alec O'Hanley: Glastonbury was a good one. That felt like a good cap to the tour, but then we just carried on touring! It is tough to pick favourites. Last night in Bristol was a blast. I'm sure Shepherd's Bush will be nice at the end of this tour.
Molly Rankin: When we played in Kentucky there was a bit of a hurricane situation. And there were fireworks about fifteen minutes before the hurricane. So we were all enjoying this very spontaneous fireworks experience and then the front speakers blew off the main stage. Then they evacuated everyone away from the main stage within the next five minutes...
Alec O'Hanley: Sam Smith included. He had the eight-minute run up to his Tom Petty single then didn't get to play it!
Molly Rankin: It was euphoric up until that point.
Alec O'Hanley: Kids are always fun to play to.
Molly Rankin: That's what's good about the UK. Most of the shows are 14+.
Alec O'Hanley: Which doesn't exist where we're from. It's either our ages or 19+.
Molly Rankin: The clubs have to stay open with liquor sales and the legalities of that skew a lot of the sentiment we have about playing for people of all ages.
Alec O'Hanley: The Brits were the first people to really champion us. We broke on this side of the Atlantic before our album came out. It feels as if audiences here were primed for what we do in that while we're hugely influenced by a lot of American college rock like REM, we also skew a little towards Mancunian and Glaswegian sounds from the same era. So I think that gave us an instant click with the UK and also the United States more so than in Canada. It's a little puzzling trying to ponder demographics and why they work the way they do but I guess that explains why we've toured the UK as much if not more than any other place.
DiS: The tour then continues throughout October, November and part of December. I guess you'll be glad to finally go home?
Alec O'Hanley: We were meant to take some time off earlier this year but gradually that seemed to evaporate. We were warned that once you get on the road there can be a tendency to never come off, and we're fighting as best we can to avert that.
Molly Rankin: It just fills up. The schedule starts off blank and then gradually fills up until it becomes completely black. We're like, "OK, maybe we'll get down in the basement one day..."
Alec O'Hanley: We have written and recorded a few demos in between various legs of the tour on the same reel to reel tape machine we made our first record on. That's now in the basement so we're doing some tracking on that between runs. That's an important muscle to keep active as well, the whole editing-demoing-recording process.
DiS: It must be difficult to focus on writing new material being on the road for so long?
Molly Rankin: It's physically difficult to be in the same place to get everyone on the same page sometimes when you're at home, because it is only for a short period of time. We're always working on new ideas but the only time we get to try them out is during soundcheck and even then that's only twenty minutes long.
Alec O'Hanley: Sometimes you get to chisel something out that you started working on back home. We did that today with a new song. But then to be able to really sink your teeth into something requires at least a week.
Molly Rankin: Who wants to spend that week with us?
DiS: You've introduced a couple of new songs into the set over the past few months - 'New Haircut' and 'Hey'. Are there any plans to record and release either of these in the foreseeable future or is it more a case of them being the first steps towards the second album?
Molly Rankin: I guess they're more of a first step towards the next album although we were thinking of releasing a single just for fun. But that also takes time which we didn't have. We did some recordings but they're still in the manipulation period.
Alec O'Hanley: We took a long time getting our first album right so to do a slapdash recording with any new songs wouldn't be true to our ethic thus far. We're musical thrills junkies. We seek that kind of rush every time we write a song, and if the document we've written doesn't give you that reaction then we'll just keep working until it does. You have to do right by the song and produce a document or relic that does it justice.
DiS: How many songs do you have ready for the second record?
Alec O'Hanley: I don't know. We have plenty of different themes and half-songs that we tend to swirl around in a big stewpot until they form on their own. We don't try to force them too much. It would be hard to attach a definite number on there. The songs we do feel reasonably comfortable about in their current incarnation we do test out live. That's why it's been good to test the new material on this tour.
Molly Rankin: Plus I think I prefer to write in the miserable months as well. I'm excited for that.
DiS: Is there any pressure from your label (Transgressive) to release a follow-up soon after the success of the first record?
Molly Rankin: They haven't said anything to us yet and I don't think they will.
Alec O'Hanley: They know better than that. We've been fortunate enough to work with good people who just let us do our thing, and know that our thing's worth doing. And also that it takes time. So there's no evil men in suits hanging over our heads or anything.
Molly Rankin: They're all music nerds at the level who are as excited as we are if anything. I think that's a better way to look at it. Excitement rather than pressure. Or at least that's what I tell myself!
Alec O'Hanley: We won't pull the Kevin Shields post Loveless thing, even though it worked for him.
Molly Rankin: Although it didn't work for Guns'n'Roses!
DiS: Do you find it difficult to walk down the street without being recognised now compared to before the album came out?
Alec O'Hanley: In the grand scheme of things we're very tiny potatoes. To be honest there hasn't been that much of a change. We might get the occasional person approach us but not a significant number.
Molly Rankin: We've never had that many awful encounters either. Most of our fans tend to be really sweet and cute.
Alec O'Hanley: Kerri (MacLellan, keyboards) gets most of the attention. She had a guy paint a picture of him and her together once!
Molly Rankin: She has a real niche demographic. She's like the beautiful nerd. Her image anyway.
DiS: Did you expect the universal acclaim that came your way off the back of the first record?
Alec O'Hanley: You sort of hope for that. We never expect it because we've been let down too many times in the past.
Molly Rankin: Having no expectations has served us rather well. It was a pleasant surprise seeing our name in all those lists even if we don't quite get "year end culture". We certainly never expected that when the record came out.
Alec O'Hanley: It was a pretty humble record too. A lot of people told us it sounded like a demo.
Molly Rankin: Someone told me they found it very derivative but good! In fact, that was pretty much the main sentence of every single bit of feedback that surfaced.
Alec O'Hanley: Which is fine. That's the nature of pop. There's nothing really new.
DiS: There's certain reference points on the record which can be picked out but I wouldn't call Alvvays a derivative record. And definitely not in the context of everything else that's around at the minute. Compared to much of what's out there it actually sounds quite fresh.
Molly Rankin: That's what my mum called it. Fresh!
DiS: If you had the power of hindsight is there anything you'd change or do differently regarding the first record?
Molly Rankin: I guess we could have remastered it a few more times or recorded some of the instrumental parts a bit better. But on the whole, I'm pretty OK with the record the way that it is.
Alec O'Hanley: The record kind of sounds like it's behind a veil a little bit. We had to do that for pragmatic engineering reasons. We probably would have enlisted the services of an engineer for the studio rather than just being three or four musicians banging like monkeys on a tape machine. At the same time, I think that amateur charm and spirit shines through. We're not revisionists. We're happy with what did eventually come out. It would have been nice to remix and remaster the record a few more times. That could have saved us some frustration but you can't necessarily pick your route to point B. You just have to take it.
DiS: Will there be a producer involved with the second record? Is there a wishlist of people you'd like to work with?
Alec O'Hanley: I don't know...
Molly Rankin: I'm not sure whether the wishlist is obtainable? I feel like it would be cool to do it ourselves. Alec had to do a lot of it on the first record.
Alec O'Hanley: I had to teach myself how to EQ. It sounds like simple stuff but taking courses on the pragmatics of studio production was a complex experience. It's a very rich world in its own right. It would be nice to be self sufficient, and by using the machine we made the last record on we hope to get there. It's a cool thing to be able to just track to tape immediately at the push of a button. The more things you can do to narrow that gap, the better. If you can capture something during a moment of inspiration rather than wait until after the moment's subsided it has to be better.
Molly Rankin: It's better to have control over as much of what we do in every part of this situation as possible.
Alec O'Hanley: I don't know if the nineties model still exists in the independent recording world any more. So I guess we're the beneficiaries of that self sufficient phase. Maybe the public is more tuned to hearing that kind of thing? Whenever I hear an Ariel Pink or John Maus record it sounds pretty raw which is great. When I can't tie a recording to any particular era I think you've succeeded. Nobody wants their music to sound dated in five years and that's basically what we're going for.
DiS: Do you see recording as being an opportunity to capture your live sound on tape, or maybe vice versa even?
Alec O'Hanley: I don't know. The recording sort of preceded the band.
Molly Rankin: We weren't a band to start with. We only became a band after we made the record. Alec O'Hanley: For me a recording is always about serving the song. You hear stories about Kiss deliberately recording their albums flat so their live shows would seem extraordinary. Whether we've done that inadvertently I don't know.
Molly Rankin: People get bored. You have to move around more. Especially with phones now. People are on Instagram within the first song. If they're not taking pictures of you they're scrolling through their feed. I don't try and appease that but at the same time, our record is sombre. So we do have to sculpt a setlist that works with a lot of different attention spans.
DiS: How do you feel about people recording songs from your live shows and uploading them to You Tube? Particularly songs that haven't yet been released.
Molly Rankin: I feel weird about that but it's out of our control so I try to look at it as people being excited.
DiS: You've been playing the odd cover version at different shows. 'Out Of Reach' by The Primitives and 'Life On The Beach' by Kirsty MacColl being two. Are there any other songs you're likely to cover in the future?
Molly Rankin: We have a dish of covers that we choose from. We've done 'Crash' by The Primitives, 'Nosebleed' by Deerhunter, 'Alimony' by The Hummingbirds.
Alec O'Hanley: We tried doing a Dolly Mixture cover but that didn't last to long. Do you know that band? One of them was married to Captain Sensible. They were great. So prolific. They're probably next on our list. The Kirsty (MacColl) cover felt good last night. There was a poster of her on the wall in Bristol.
Molly Rankin: We hadn't done that cover for a while and then we decided to bring it back. We love her and it's so much fun. Especially in the UK.
Alec O'Hanley: It didn't cause a ripple in Canada or the States where people haven't heard of her but it's different altogether over here.
DiS: How do you feel about people covering your songs? Ben Gibbard's recent cover of 'Archie Marry Me' being the most obvious example.
Alec O'Hanley: It's nice when people bother to sit down and learn a song. Quite flattering actually.
Molly Rankin: I met his girlfriend when we were on tour with Real Estate and she was working with St Vincent. She told me her boyfriend was at home playing our song on his piano and I didn't know who or what she was talking about. Then we got off stage at Glastonbury and bumped into her again with Ben Gibbard and I was like, "So that's who your boyfriend is?!!"
DiS: What advice would you give to new bands just starting out?
Alec O'Hanley: Fill your ears with objectively good music. Listen, listen, listen. Write, write, write.
Molly Rankin: Feel free to say no to any bad ideas people try to bestow on you. Because if they sound like bad ideas then usually they are. And you'll regret it. Also, it's your own thing so do as much as you can yourself.
DiS: Aside from playing live and touring, what else do you have planned for the rest of the year?
Alec O'Hanley: We're definitely going to be doing a lot of writing and recording between now and the end of the year.
Molly Rankin: We'll probably have to go back to our day jobs more.
DiS: You all have day jobs?
Molly Rankin: If I can get mine back! Kerri's a nanny, Brian's a brunch cook, Phil's a professional streamer.
Alec O'Hanley: I've got a good boss. He's as empathetic an employer as you could find. I work in a guitar store.
Molly Rankin: Most people I know that play in touring bands have day jobs. It wouldn't be sustainable otherwise. It's funny when I watch shows like 'Nashville' where five people will be sitting in a room going, "We have a number one hit on our hands! Let's get it to the radio!" as if that's it, job done. It's so far removed from how things actually are.
Alec O'Hanley: Bands do have to stay on the road if they want to make ends meet.
DiS: Have you ever reached that point where you've considered whether being in a touring band is the right thing to do?
Alec O'Hanley: Yeah, there are times when you think about why we're doing it. Occasionally things can get a little disheartening and shades of groundhog day start creeping in.
Molly Rankin: But at the same time it's been an absolute blast being able to play in all corners of the world, see places I've never seen before and have people show up every night mouthing the words to our songs. Sometimes I forget how lucky we are.
For more information on Alvvays including releases and forthcoming live shows visit their official website.
![101193](http://dis.resized.images.s3.amazonaws.com/540x310/101193.jpeg)
In Photos: Boomtown Fair 2015 @ Winch...
DiScover: Autobahn
Q1 Digest: Most Read and Editor's Recommended R...
DiS speaks to Weezer's Rivers Cuomo
Scotch Broth: Idlewild discuss Everything Ever ...
Battles: Tyondai Braxton talks Mirrored
Kate Bush, Hammersmith Apollo 26/8/14: "There's...
Drowned In Sound's 40 Favourite Songs of 2014
DiS does Wireless... half the time, anyway
Discography Reassessed
The Story So Far: Pere Ubu in Review


text:
Q: How can I quickly close multiple VI instances in different GNU-Screen tabs? I often have around 10 tabs in GNU-Screen open with all of them having vim open to a different file. If I just kill the Screen session, then VIM doesn't cleanup (.swp files are still there), so I usually have to go to each tab individually and type ":wq" and the "exit" to kill the screen tab. Any faster ways to do this?

A: killall vim

;-)

A: I do something similar and ran into the same problem. What worked for me was to just turn off the creation of .swp files so vim doesn't care if I close the whole session at once. In my .vimrc:
set noswapfile

Of course this only works because I'm in the habit of saving often and almost everything is in version control so I could get it back if some catastrophe happened. Your mileage may vary if you have a different use case or work flow.

redpajama_set_name: RedPajamaStackExchange


text:
WCRM SKY 102.1FM IS A DW AFFILIATE.
Listen to the following DW programs of Sky FM
1. DW World News African Link
2. World in Progress
3. 77 percent
HomeAll PostsPROGRAMS
OFIE NE FIE HOSTED BY NANA BAAFI
Ofie ne Fie, hosted by Nana Baafi comes to you every Saturday from 10 in the morning till noon on sky 102.1 fm. This program brings listeners a blend of 20th century highlife popularly known as adadamu or Boga highlife in Ghana local dialect from the likes of The legends Nana Ampadu who first recorded his first song in 1967 , Kofi Sammy , Alex Konadu , J A Adofo, Ben Brako, George Darko etc These Musicians promote positive thinking and also inspire the youth with their choice of lyrics
DRIVE TIME WITH MC KIKI
The Drive time show on sky fm is a 2 hour 30 minutes radio magazine program aired on Mondays and Fridays at 4:30pm to 7:00pm. It is also streamed live on the Skyfm facebook page The show is hosted by MC KIKI and a list of co hosts and guests for interviews. Segments on the show includes, today in history, Entertainment News and Drive talk. Listeners are also allowed to call in to share their views on the various issues discussed.
YOUNG AND CURIOUS BY GINA CARIS
Finding purpose in life is not a single event for all and for young people, their curiosity pushes them to explore life. These experiments often come with making mistakes and learning from them which eventually helps them create an identify. The young and curious show on sky 102.1fm takes you to the world of young people. It captures among others the everyday decisions and challenges of young people. Make a date with Gina Caris on Sky 102.1fm, Saturdays at 12noon on the young and curious show.
THE PULPIT BY RICHOCCO
The pulpit show hosted by Richoco is aired on Sundays at 4:30pm to 6pm. It captures various issues in the body of Christ ranging from lifestyles of minsters of God, the sermons they preach and generally how today's church is run. Listeners are allowed to phone in and ask questions that bothers their minds on Christianity whiles Richoco and his panelists attempts answering with biblical references. The pulpit is streamed live on the Sky fm Facebook page.
ABRABO MU NSEM WITH RICHOCCO
Abrabo mu nsem in English is ISSUES OF LIFE. As the name of the show suggests, it creates the platform for the discussion of everyday life challenges and recommend solutions. Areas discussed on the show includes Child Education Divorce and Abused Marriages Sex Education Health and Finance in marriage Join Richocco and his team, Tuesdays at 4:30pm to 6:00 pm as they talk about Life.
JOURNEY TO FREEDOM WITH JASMINE
Life they say is a journey, and the only impossible journey is the one you never begin. The journey to freedom show with Jasmine on Sky 102.1fm creates the platform for survivors to tell their stories on the mountains they climbed. Their words we believe will become a page in someone else's survival guide. The Journey to freedom airs with Jasmine is on Thursdays at 5:00pm on sky 102.1 fm


Auxiliary members are encouraged to get involved and stay informed on local and national issues of special interest to the organization. They keep in close contact with their legislative representatives about issues which concern veterans, young people, and entire communities. Auxiliary members know there is strength in numbers. Many beneficial laws have been passed because of Legion and Auxiliary support.


Tech Resources to help parents keep their students safe and learning!
APPS that will keep your child learning!
Door 24 Plus is a math fluency app that harnesses the power of game design to help develop students' skills in both fact fluency and computational fluency. It provides targeted practice in the use of basic facts, number sense, and algebraic thinking.
This app was developed by NCTM Illuminations. The web version of this app and supplemental resources for teaching are available at illuminations.nctm.org.
Breeze through vocabulary building with Bluster!
This word matching game develops vocabulary and word understanding for school-aged children, or anyone brave enough to battle the elements.
Shine bright in single-player mode as you learn and practice important word skills. Match rhyming words, prefixes and suffixes, synonyms, homophones, adjectives, and more.
Collaborate with a friend in team mode. The multi-touch iPad screen allows both players to play simultaneously, so you can work together to weather the vocabulary storm.
Switch to versus mode and play head-to-head for the ultimate test of your lightning quickness. Disrupt your opponent with weather attacks like tornadoes and blizzards - it's thunderous fun and just might give you the edge you need to reign supreme!
Bluster includes over 800 vocabulary words. Players choose a skill to practice and then try to make matches of three. Ten matches wins a round.
• Three different play modes - including two-player action.
• A variety of grade level appropriate content.
• Engaging animated gameplay with sound effects.
• Head-to-head and High Scores tables.
• Plays on the iPad in both landscape and portrait mode.
• In app purchases for additional vocabulary.
• The iPad version includes an option to show select number sentences... one at a time or all types that were selected.
• The iPod version to show one randomly select number sentence at a time.
Designed as part of the NumberSense Project at Augustana College in Rock Island, IL.
Fraction Bars you can manipulate!


text:
George Floyd's death was 'appalling and avoidable' - German government
Navalny leaves Germany on Russia-bound jet five months after being poisoned
End of Merkel era begins as German CDU picks new party leader
World migration down 30 percent due to pandemic: UN
Siraj, Sundar reportedly abused by Gabba crowd
Razzaque for exporting agro products to Germany
"It is an appalling and avoidable death that shakes you up. We in the federal government are following closely what is happening in America right now"
Germany's government is "shocked by the death of George Floyd" in the United States.
German Chancellor Angela Merkel's spokesperson made the statement on Wednesday, reports the CNN.
During a regular government news conference, Steffen Seibert said: "The death of George Floyd (...) shocked people in Germany and all over the world, it shocked the federal government too."
"It is an appalling and avoidable death that shakes you up. We in the federal government are following closely what is happening in America right now."
Seibert went on to say: "We hope that this violence ends and we hope that the many wise and humane voices that exist in America too, those who are peacefully working for improvements (...) who are striving to end racism, are being heard."
"I am sure there is racism in Germany too," Seibert added, saying "every society, including ours, is called upon to continually work against this."
Germany / United States (US) / Racisim


text:
She Said It Was AMAZING (The "I'd Rather F*ck You"…Eazy E Edition)
April 10, 2017 by admin Leave a Comment
You must forgive me…I do not typically start my Mondays like this. But she (an anonymous friend) said IT WAS AMAZING four days ago and the word is still lingering in my mind. Fuck she mean AMAZING?! I had not said that word in like 7 years! 😳 No disrespect to any of my lovers but it is true. My last real Big O was in May 2010…with Phoenix. Now my friend is dropping words like Amazing and I'm like…where do they do that at?! Most of my friends (female/male…straight/gay) are married so no one in my circle generally throws around the word Amazing when it comes to sex. I think Harmony may have been the most recent (until now) to utter that word…last Fall about a guy she was seeing. But Harmony is my only friend that lives for Amazing experiences.🙌🏽 What got me about my anonymous friend saying that she had Amazing sex with a guy she is secretly seeing…is she is not the type to easily use the word Amazing. And I could hear it in her voice…as if she was falling right back into the sexual trance he put her in…just by reliving a chapter in her sex chronicles. 😳 Fuck she mean Amazing? Girl…what did he do to you? Second by second…minute by minute was filled with a built up passion they had both been dreaming about for nine months. He innocently forgot to inform her that he was packing heat. 😳 Not a pistol penis…more like a missile that was about to invade her space. They were going to war…just the two of them and her neighbors were destined to hear about it ALL NIGHT LONG! 🙌🏽 It wasn't just the fact that he had a gigantic penis that made their sex Amazing…I could hear this as her voice trembled. We had both dated men in the big dick club…heck the Ex Factor is a member…but she spoke of deep desires, him whispering sweet nothings in her ears as they broke dawn, and him comforting her through a series of sex positions. She…said…it…was…AMAZING! He stayed with her…in a moment in time that they would both treasure. She wanted to keep him to herself…all to herself…and that was why they were secretly seeing each other. Once friends and now lovers…they needed to figure out what they were to each other before announcing it to the world. Yet she had to tell me that it was Amazing. She could not hold it in any longer…and as if she was still biting her pillow in throws of ecstasy…she managed to get out the word AMAZING! 🙌🏽 Fuck she mean Amazing? I…I…need details! I asked my friend to not hold back and to tell me everything because I cannot tell the last time…I had been eaten alive with cries of passion. I needed to remember what Amazing entailed. "I shook…I shivered…and then my body betrayed me and exploded into a sea of ecstasy…so much so that he may have heard me mourn that it was AMAZING," she said. "It was our first time and I was not ready for him to know all my pleasure zones. But it was like he had always had a map," she breathlessly confessed. Man…she said he was Amazing especially at dawn when he spoke of his feelings for her. My friend was not expecting any of this. Especially to hear that he had been waiting on only her…wanting only her…desiring only her. She said it was Amazing when he held her and she just knew that this night would forever go down in history. There was no where nor no one else he was rushing to. He was there with her…thinking only of her. ONLY HER😳She said it was AMAZING and I was instantly jealous! Maybe next time she can record the sounds…I needed to know what it felt like to be desired like that. I needed to hear it…don't need the visual…just want to know that those sounds are still possible… You see I really love the Ex Factor but he has gotten very comfortable and lazy. Because he knows how much I love him…he no longer feels like he has to try. His family (which is understandable) and friends always come before me. I…am…an AFTERTHOUGHT and even though he tries to justify it…it's greatly affected our sex life. Most of the time I have no desire for him to touch me. The love is still there but because I do not feel secure and valued…I no longer desire him. I get that the way things are at the beginning of a relationship is not the way it is when you have been together a long time…but I'm not his wife. The Ex Factor should not feel he HAS ME! I wholeheartedly belong to myself. And even if I was his wife…I would hope he would realize that love alone with no follow through/acts of care can die. Maybe we are just in a rut…but still when my homegirl said it was AMAZING…I could not help but mourn the part of me that had died. My sexual being. The part of me that Crazy from college and Phoenix in my adult life…had tapped into. I miss having AMAZING moments. ~KJM enticed by the word AMAZING on this Charm School Monday😉
Anonymous on My 38th Trip Around The Sun
Anonymous on The Vivid Dream (The 2am And Very Personal Version)
Anonymous on The Wife (The Pieces Of Us That We So Easily Gave Away Edition)


text:
Homeschooling Teen
- A monthly online magazine BY Homeschool Teens... FOR Homeschool Teens!
Homeschooling High School
Intro to Homeschool Electives
Homeschool Electives
"Best in Class" Awards
Best in Class Award Criteria
Teen Homeschool Conferences
Homeschool Transcripts
"No Controversy" Hides a Growing Environmental Concern
by Eleanor Frances
Melinda Gates [wife of Microsoft founder Bill Gates] means well. She wants African women to use contraceptives. She is reaching out to poor African women, and her idea sounds helpful till you consider how Africa's drinking water, often lacking modern treatment facilities, is negatively affected by the estrogen contamination that accompanies widespread contraceptive use (Njemanze). So, although Gates has promoted contraceptives with the slogan "No Controversy," handing out contraceptives to African women is anything but noncontroversial.
Birth control pills contain estrogen, which controls a woman's level of ovulation. Adding hormones to her body makes her body think it's already pregnant. Estrogen coming from birth control pills increases the normal hormone levels in a woman's body in order to prevent a baby from implanting in her uterus. Estrogen does not break down in a woman's digestive system. When women excrete the medicine, the urine goes into rivers. So, even if a community has a collection for unused medicine, such pharmaceuticals still pose a hazard to drinking water. The water purification systems, even in this country, currently do not remove estrogen or are too expensive (Dery "Troubled" 5).
Westernized countries with a history of contraceptive use are reporting contaminated water and odd changes in fish populations. "A recent report from the U.S. Geological Survey confirms past findings that fish are in trouble. They're turning up with lesions and intersexed, meaning they have both male and female characteristics. WBHM's Tanya Ott talked with University of Alabama at Birmingham fish biologist Rob Angus about the problem and what it means for humans." "Fish are in Trouble." Wbhm.org 8 Dec. 2009 http://www.wbhm.org/News/2009/fishestrogen.html
This is a concern because even in trace amounts, the chemical hormone can disrupt the normal development or functioning of a species. When normal fish take in the hormones, it feminizes male fish (Hagerman). The hormonal imbalance produces reproductive changes such that the male fish exhibit female reproductive characteristics. So, the artificial hormone mimics, interferes with or blocks the normal development of the male fish. Eventually, the fish can no longer reproduce (Kidd).
Sohn, Emily "More Hermaphrodite Fish in U.S. Rivers." Discovery News. 15 Sept. 2009 http://news.discovery.com/animals/more-hermaphrodite-fish-in-us.html
Admittedly, not all Endocrine Disruptors or EDCs are from contraceptives. Agricultural use of pesticides as well as widespread use of plastic containers and other plastic uses contribute a heavy dose of additional estrogen contamination. The point is that while society cares deeply about certain harmful chemicals passing into the food chain, birth control chemicals— just as harmful — have continued to be prescribed by doctors and health professionals and promoted by women like Melinda Gates. In particular, Melinda Gates has gained notoriety for her comment that pushing contraception poses "no controversy."
Human Life International. "No Controversy?" 12 July 2012. http://factsformelindagates.com
The controversy is that companies who sell contraceptives and abortion are backing her efforts to promote contraception in a Third World country. The video above notes the bias of Melinda Gates, who partners with the biggest abortion providers in the world, including Planned Parenthood and Marie Stopes. Melinda Gates is not a neutral benefactor, in other words, and because these groups have been associated with population control efforts, there is reason to question their initiatives (Peters, Oas).
Controversy means there is disagreement over what should be done and how. In the case of poverty in Africa, there are many good ideas, such as improving water and sanitation, building better medical facilities, and contributing to educational efforts. Such efforts are far less intrusive on African families, values, and cultures and do not pressure Africans to use contraception. Africans live in extended family relationships, for instance, and do not regard the bearing of children as exclusively a woman's choice. Birth control does nothing to help families, reduce the spread of HIV infection, or enable women to gain education or jobs.
Moreover, contraceptive drugs are rated with asbestos and radium as Group I carcinogens by the World Health Organization (Gilbert). Therefore, promoting contraceptives pits reproductive rights and privacy groups against doctors and environmentalists ("Birth Control"). How to address the many needs in Africa is the subject of debate, and it is actually extremely controversial to assume that limiting the population through birth control is a valid way to solve poverty. The controversy surrounding Melinda Gates has been visually epitomized by a popular poster or meme that has circulated on Facebook:
"Melinda Gates Solution." http://www.catholicmemes.com
http://catholicmemebase.tumblr.com/post/31399318184/melinda-gates-solution
There is also controversy surrounding the disposal of contraceptive drugs, especially the effects contraceptives are having on the environment as well as health effects in humans. Obianuju Ekeocha, a biomedical scientist from Nigeria, has commented: "In Africa, be rest assured that both in the biggest cities and smaller rural villages, sewage constitutes a real problem. So as $4.6 billion worth of drugs, IUDs and condoms get used, they will need safe disposal. Can someone please show us how and where will that be? On our farm lands where we get all our food? In our streams and rivers from whence comes our drinking water?" (Ekeocha). Where there is a health cancer or environmental risk, there is always concern and, yes, controversy.
The contraceptive pill has clearly been linked to increased incidence of breast cancer in women (Gilbert). Professor Paul Fowler, a researcher at University of Aberdeen said "It's notable that incidences of breast and testicular cancer and of fertility problems in humans are increasing, while populations of animal groups as diverse as amphibians and honey bees are in decline." (qtd. in "Scientists").
Others think this is an overblown concern. In a pro-birth control article in Contraception Journal, the authors argue that the amount of estrogen found in water is too small to matter (Moore et al). The problem is that a lot of women are taking birth control pills, over 100 million women worldwide (White). Moreover, the scientists who are concerned about estrogen contamination acknowledge that even in trace amounts, estrogen pollutants are hazardous.
Estrogen contamination even in tiny amounts represents a grave threat, and it is striking that researchers report that fertility and gender concerns appear to be on the rise. Scientists have increasingly noted strange anomalies: "Girls are experiencing puberty at unnatural ages, women are having trouble bearing children and research has shown an increase in the percentage of females among newborn children. Scientists are saying that these things are due to an unsafe amount of the hormone estrogen in our water" (Dery "Estrogen"). These trends suggest that humans are very likely being affected by even trace amounts of birth control in the water and food supply, and indeed, estrogen has been linked to lowered sperm counts and cancer in males well as increased infertility ("Scientists," Oas, Hagerman).
Africans regard the Melinda Gates contraceptive program as highly controversial, and with regard to health and pollution effects have "decried the irresponsible 'dumping' of contraceptive pills in many African countries by international funding agencies and governments without regard to health and environmental issues" (Njemanze). They are right to be concerned.
Estrogen contamination has not been limited to the United States but has also been detected in Africa. Dr. Philip C. Njemanze has noted these problems affect Africa's food supplies as well as water, citing studies in Gauteng South Africa: "The researchers discovered many strange, inter-sex fish, which had both male and female reproductive tissue. Any change in the gender ratio or abnormality in reproductive tissue can adversely affect a population of fish, potentially reducing it with each generation. It also threatens the entire food chain of the aquatic eco-system" (Njemanze). Africa, already hard hit by food shortages, does not need estrogen contamination to further jeopardize food sources.
Rather than focusing their work in African countries on pressing needs such as helping build wells and setting up water- cleaning technology, Melinda Gates is supplying contraceptives which serve to pollute water supplies and endanger already limited food supplies. Obianuju Ekeocha, who wrote an open letter to Melinda Gates, has suggested that the Gates Foundation could support NonGovernmental Organizations or NGOs with a specifically women-focused mission, such as protecting women from sex-trafficking, prostitution, forced marriage, molestation, and domestic violence. Ekeocha observed: "Many of these NGOs do not have much success because they are not well-funded. Though most of them have good intentions, they lack professional input from those such as psychologists, logisticians or medical personnel needed to tackle various problems (Ekeocha). Genuine concern for women recognizes their need for committed family relationships.
Contraceptive use does not support the kind of committed relationships society needs. Obianuju Ekeocha is from Nigeria and a member of the Igbo tribe. She is a biomedical scientist in Canterbury, England. In her letter to Gates, Obianuju Ekeocha notes that Africans love their extended families. She said: "I see this $4.6 billion buying us misery. I see it buying us unfaithful husbands. I see it buying us streets devoid of the innocent chatter of children. I see it buying us disease and untimely death. I see it buying us a retirement without the tender loving care of our children" (Ekeocha). http://concernedforlife.blogspot.com/2012/09/an-african-woman-responds-to-melinda.html
The Melinda Gates Foundation wants African women to abandon their African histories, knowledge and resources to promote reproductive rights. African women have passed along knowledge about female fertility, for instance, more in keeping with what is termed natural family planning than contraceptives ("Unleashed"). Therefore, it is a question whether Africans really want contraceptives over more crucial assistance or are they accepting the contraceptive agenda in return for gaining water and food aid. Colonialism is the practice of domination, which involves the subjugation of one people to another, and Africa is no stranger to such interference.
http://www.leastofthese.net/our-work/our-passion/
Mostly, Africans reject the patronizing outlook of philanthropists who claim to know better how they should regulate their lives than they do, drawing on generations of family and tribal customs as well as extensive faith traditions. John Cardinal Njue, Chairman of the Kenya Episcopal Conference of Bishops in a letter titled Let us Uphold Human Dignity, wrote: "We cannot allow our country to be part of an international agenda, driven by foreign funds and by so doing, losing our independence and our African values of the family and society"(Peter Balinski, "Kenya").
Melinda Gates has no right to hold Africans hostage to Western liberal values or to any other values than their own. Imposing a contraceptive program as a solution to women's poverty in Africa—one that gets "sold" as charity by the attractive Melinda Gates, and backed by pretty phrases like "reproductive rights" —is very controversial.
African Family Image
http://www.whats4eats.com/content/region-africa-african-family-image
"Birth Control Pills Poison Everyone? Environmentalists Silent on Threat From Water Tainted with Estrogen." WorldNetWeekly 12 July 2007. http://www.wnd.com/2007/07/42520/
Balinski, Peter. "Kenya Bishops Slam Melinda Gates' Contraception Plan for Africa." The Richard Dwakins Foundation. 4 Aug. 2012. http://old.richarddawkins.net/articles/646650-kenya-bishops-slam-melinda-gates-contraception-plan-for-africa
Balinski, Thaddeus "Scientists: Harmful Hormones from Birth Control Pill Can't Be Filtered Out In Sewage Treatment. LifeSiteNews. 12 Sept. 2012. http://www.lifesitenews.com/news/scientists-harmful-hormones-from-birth-control-pill-cant-be-filtered-out-in
Dery, Luke. "Estrogen Pollution Making Ripples." The Massachusetts Daily Collegian 20 Sept. 2012. http://dailycollegian.com/2012/09/20/estrogen-pollution-making-ripples/
Dery, Luke. "Troubled Waters: Removing Estrogen from Our Water Supply." The Scientia Review 2009. http://www.scientiareview.org/pdfs/169.pdf
Ekeocha, Obianuju. "Nigerian Woman Writes to Melinda Gates: We Don't Need Your Contraception." Catholic Online 20 Aug. 2012. http://www.catholic.org/national/national_story.php?id=47264
"Endocrine Disruptor." Canadian Center for Occupational Health and Safety. 4 J uly 2011. http://www.ccohs.ca/oshanswers/chemicals/endocrine.html
Gilbert, Kathleen. "Surgeon: Birth Control Pill a 'Molotov Cocktail' for Breast Cancer." LifeSiteNews. 6 Dec. 2010. http://www.lifesitenews.com/news/surgeon-birth-control-pill-a-molotov-cocktail-for-breast-cancer/
Hagerman, Eric. "Something in the Water Is Feminizing Male Fish. Are We Next?" PopSci. 30 Nov. 2009. http://www.popsci.com/science/article/2009-11/what-feminizing-so-many-male-fish-our-rivers
Human Life International. "No Controversy?" 12 July 2012. http://www.youtube.com/watch?feature=player_embedded&v=IuitL4XhDAA
Kidd, Karen, et. al. "Collapse of a Fish Population After Exposure to a Synthetic Estrogen." Proceedings of the National Academy of Sciences of the United States of America. 29 March 2007. http://www.pnas.org/content/104/21/8897.abstract
Moore, Kirsten , Kimberly Inez McGuire, Rivka Gordon, Tracey J. Woodruff. "Birth Control Hormones In Water: Separating Myth From Fact." Contraception Journal. Association of Reproductive Health Professionals. http://www.arhp.org/publications-and-resources/contraception-journal/august-2011
Murray, Iam. "Pill As Pollutant: A Really Inconvenient Truth." National Review Online 27 April 2008. http://www.nationalreview.com/articles/224265/pill-pollutant/iain-murray
Njemanze, Philip C. "The Irresponsible 'Dumping' of Contraceptive Pills in Many African Countries." 14 Feb. 2008. http://www.chidicon.com/files/ENVIRON_CONTRA.pdf
Oas, Rebecca. "What the Pill is Doing to Our Water Supply." Life Site News. 17 May 17, 2012. http://www.lifesitenews.com/news/what-the-pill-is-doing-to-our-water-supply/
Peters , Thomas. "Melinda Gates Raises $4.6 Billion to Fund Pro-Abortion Groups in Poor Countries." LiveAction News 12 July 2012. http://liveactionnews.org/international/melinda-gates-raises-4-6-billion-to-fund-pro-abortion-groups-in-poor-countries/
"Unleashing the Power of a Woman's Cycle." NaproTechnology.com 2006. http://naprotechnology.com
White, Hilary. "Study Confirms Estrogen in Water from the Pill Devastating to Fish Populations." LifeSiteNews. 18 Feb. 2008. http://www.lifesitenews.com/news/archive//ldn/2008/feb/08021805
Wise, Amber, Kacieo O'Brien, Tracy Woodruff, "Are Oral Contraceptives a Significant Contributor to the Estrogenicity of Drinking Water? Environmental Science Technology 14 Sept. 2010. http://www.rhtp.org/contraception/documents/UCSFPaper.pdf
Tags: Africa, Bill Gates, contraceptive, environment, estrogen, Gates Foundation, Melinda Gates, no controversy, pill, pollution
Time limit is exhausted. Please reload CAPTCHA. − four = two
Sign up for the e-zine - it's FREE!
Enter your e-mail address to receive each issue, posted on or around the first day of every month. (Don't worry, we will never sell or share your info.) BONUS: Subscribers receive a monthly freebie!
This site is an Amazon affiliate. Clicking through our links gives us a small commission. Can't see an ad above? Please turn off your adblocker. Thank you! :-)
Juan Tabo on Want to Enlist in the Space Corps?
HST on Introduction to Graphic Design
Deborah Smith on Introduction to Graphic Design
anime art bible book business career careers Christian Christianity college education elective engineering ezine game God health high school history homeschool homeschooling homeschooling teen infographic job jobs learning magazine movie music online poem poetry review scholarship science STEM student students tech technology teen teens travel university writing
HomeschoolingKidsMagazine.com
HomeschoolLibrary.info
FamousHomeschoolers.net
HomeschoolPatriot.com
LittleBrickSchoolhouse.com
MinifigCity.com
ArizonaEdventures.com
This Site is Owned by:
KnowledgeHouse.info
Become a Sponsor | Advertise With Us CONTACT: mail@homeschoolingteen.com
Homeschooling Teen is listed as #25 in
The 50 Best Blogs About Secondary Education
at BestCollegesOnline.com
HOMESCHOOLING TEEN MAGAZINE © 2016 Frontier Theme


text:
Judiciary Lays The Foundation For POCSO Act
Population First
Shalini Phansalkar Joshi. J, Former Judge, High Court of Bombay, writes on how our judicial system built the foundation for POCSO.
Sexual abuse of children, in one form or another, has existed in almost all societies throughout history. However this is generally not acknowledged. The reason could be because such abuse is shrouded in secrecy and its acknowledgment invites dishonour and stigma. The denial of its existence however makes the child more vulnerable to abuse. Child sexual abuse can take place in various forms and degrees, entailing different consequences and impacts. Just as, it can be brutal, it can also be subtle; it can be physically violent, or it can be without touching the child; it can be oral or by facial expressions and body language. Merely engaging a child in showing pornographic material also amounts to sexual abuse. Just as use of criminal force for violation of modesty of a girl is an offence involving sexual abuse, fondling or touching the child in a suggestive manner is also a form of sexual abuse. Victim subjected to child sexual abuse need not necessarily be girls, a male child is equally susceptible to it. Offenders are not always strangers or persons older than the child, they could be known to the child and of the age of child. As a matter of fact, in more than 80 percent of cases, the abuser is someone known to the child, could be a close relative like father, brother, cousin, neighbour or teacher. Despite that, incest and child sexual abuse are generally dismissed as aberrations, rather than deep rooted problems within the Indian family. As far back as 1996 in the judgment of State of Punjab vs Gurmit Singh AIR 1996 SC 1393, apex court has acknowledged its existence by observing that, "of late crimes against children in general and of sexual abuse in particular, are on the rise. It is an irony that while we are celebrating children's rights in all spheres, we show little or no concern for his/her honour and right. It is a sad reflection on the attitude of indifference of the society towards the violation of human dignity of the victims of sexual abuse, especially when victims are children."
It is a matter of record that the recently enacted law 'Protection of Children from Sexual Offences Act, 2012 is an outcome of the directions given by the judiciary. It prescribes child –friendly and victim-friendly procedures for investigation and trial of such cases and further provides for establishment of Special courts.
In the landmark judgment of Madan Gopal Kakkad vs Nawal Dubey (1992) 3 SCC 20 , the factual matrix of which, unfolded an account of a sordid and obnoxious incident, wherein a Medical Practitioner, was sexually assaulting and molesting young girls. This was not only in utter disregard of the universal moral code, of his professional ethics and values, but also in flagrant violation of the law of this Country. The apex court convicted the accused for the offence u/s 376 I.P.C. and sentenced him to R.I. for seven years and fine of Rs 25000/- in default R.I. for one and half years. The court also ordered the fine amount to be paid to the victim. In its resounding words the apex court pronounced 'Justice Demands, the Court Awards'. Before parting with the judgment, with deep concern, the court opined out that, "though all sex assaults on female children are not reported and do not come to light, yet there is an alarming and shocking increase of sex offences committed on children. This is due to the reasons that children are ignorant of the act of rape and are not able to offer resistance and become easy prey for lusty brutes who display the unscrupulous, deceitful and insidious art of luring female children and young girls. Therefore such offenders who are menace to the civilized society should be mercilessly and inexorably punished in the severest forms. We feel that judges who bear the Sword of Justice should not hesitate to use that sword with the utmost severity, to the full and to the end if the gravity of the offences so demand."
Also read: Judiciary Promotes Equality In Its True Spirit
Taking note of the fact that the sexual abuse, to which children, are subjected like fondling, kissing, inserting fingers in private parts, etc. do not come within the ambit of traditional definition of 'violation of modesty' and 'rape, in the path breaking judgment of Sakshi vs Union of India AIR 2004 SC 3566, the apex court has through an order in 1999, directed the Law Commission to review the law on rape to suggest suitable changes and further directed the legislature to amend the law accordingly. Further, taking note of the system-induced trauma faced by child victims while giving evidence in the court, as the mere sight of the accused may induce an element of extreme fear in the mind of the victim or can put the victim in a state of shock and in such a situation child may not be able to give full details of the incident which may result in miscarriage of justice, the Supreme Court has, in this judgment given various directions like providing a so that the victim does not have to undergo the trauma of seeing the body or the face of the accused. It was further held that, as often the questions put in cross-examination are purposely designed to embarrass or confuse the victims of sexual abuse, the object being that, out of the feeling of shame or embarrassment, the victim may not speak out or give details of certain acts committed by the accused, it was directed that such questions be given in writing to the Presiding Officer of the Court, who may put the same to the victim in a language which is not embarrassing. It was further directed that whenever a child victim of rape is required to give testimony, sufficient breaks should be given as and when required. These directions were in addition to the directions given in the judgment of State of Punjab vs Gurmit Singh, like recording the evidence of the victim in camera, protecting her anonymity completely and the trial of the case being conducted preferably by lady judicial officer.
Sexual abuse of children, in one form or another, has existed in almost all societies throughout history. However this is generally not acknowledged. The reason could be because such abuse is shrouded in secrecy and its acknowledgment invites dishonour and stigma.
It is a matter of record that the recently enacted law 'Protection of Children from Sexual Offences Act, 2012 is an outcome of the directions given by the judiciary. It prescribes child –friendly and victim-friendly procedures for investigation and trial of such cases and further provides for establishment of Special courts. One may say, therefore, that the law on the subject of child sexual abuse, both substantive and procedural, is the result of judiciary's initiative, persuasion and efforts.
Shalini Phansalkar Joshi. J, Former Judge, High Court of Bombay, is guest writer with Population First. This series is being published in collaboration with Laadli. The views expressed are the author's own.
Also read: Judiciary Re-Interprets Legislation To Protect The Rights Of Muslim Women
child –friendly and victim-friendly proceduresIndian judicial systemPOCSO ACTProtection of Children from Sexual Offences Act 2012Sexual abuse of childrenSexual abuse of children and judiciaryShalini Phansalkar Joshiviolation of modesty of a girl


Salvaged Strawberry: What I'm Loving!
Attention, friends. (claps symbols together) I think this week, I have discovered some of the cutest finds EVER. DO I say that every week? Maybe I do. But this week, I really hit the jackpot.
This amazing bike bar cover by Meredith! Need it! Want it! Wouldn't it look so cute on my bike?
So, you know me and my obsession with florals. Love! Love! Love! this dress from Sally Jane Vintage. And the back is amazing!
Um, look at these bookends. I think I can now cross at least three friends of my Christmas buying list!
These lovelies are all from Knob Creek Metal Arts.
My love rides year round. These might neet to go on our shelves.
Miss. Morby, are you seeing these?
I think I need these for my poetry collection. I really do. How many bookends does one really need, friends?
Marisa's whole outfit is amazing here. That dress? The jacket and hat? Those shoes? Yep, love it all! These colors are so vibrant, too! I am a new fan and follower of her cute blog.
What I'm loving MOST this week?
My dearest Cayla. Who's been gone since Friday. I miss her smile every morning and her kisses every night. Really folks, this has been way harder than I thought with her being gone. I cannot wait til she's back. My hearts a hurtin for my better half.
p.s. Still no camera! I am going bonkers! Turns out C's fam has it, but goddess knows when it will find its way to me. I would normally borrow C's camera but she is on a canoe trip! Sorry for the lack of posts! I promise I will make up for it as soon as I get a camera! gah!
I love those bookends! I just might need those kitty ones, they are too cute!
It is no fun missing the one you love, hope she is home soon!
These are some of the cutest finds ever! I wish I could thrift something like that camera bag, it's pretty amazing. Love the pic of you and Cayla, we have a similar looking tandem bike! I hope she's coming home sooooon! HUGS!
Those bookends are amazing! Love the fish and bike ones!
I want those cat bookends, and you and Cayla are adorable.
Hi, again, Amanda! I'm happy to have met you, too! ;D And thanks for the heads up, I'll check the giveaway! I am now following you, btw :p.
I adore ALL of this! I wanted to choose something specific to comment on, but I just can't decide what...these are all great!
Those book ends are amazing. I really like the bicycles. Amy looks great in your dress, the colors look great on her.
That camera bag is perfection and I love the tangible joy in the last pic!


NEXTANDCO INFRA PRIVATE LIMITED is a Private Company limited by Shares. It is registered with Registrar of Companies, Kolkata on Feb 25, 2019.
Current Status of Nextandco Infra Private Limited is Active.
There are 2 Directors associated with Nextandco Infra Private Limited. They are: Nitish Mandal and Saurav Sarkar.
Corporate Identification Number (CIN) of Nextandco Infra Private Limited is U45400WB2019PTC230673 and its Registration Number is 230673. Its Registered Address is 'C/O SATISH SARKAR , DAG NO.78, SOUTH CHANDAMARI,KALYANI, NADIA KALYANI Nadia WB 741235 IN'.
xxtxxh.xaxxaxx9xx@xxaxx.xxm Recently Registered Company; Email hidden.
No Charges found for "NEXTANDCO INFRA PRIVATE LIMITED".
Are you the owner or authorized representative of 'NEXTANDCO INFRA PRIVATE LIMITED'?
You may link to "Profile Page" of "NEXTANDCO INFRA PRIVATE LIMITED" in your websites (or) blogs.


text:
Mattis laughs off Trump criticism: 'I guess I'm the Meryl Streep of generals'
Former Secretary of Defense James Mattis on Thursday laughed off the news that President Donald Trump had called him "the world's most overrated general," joking that he's not just an overrated general, but the greatest overrated general.
"So I would just tell you, I'm honored to be considered that by Donald Trump because he also called Meryl Streep an overrated actress," Mattis said at the annual Alfred E. Smith Memorial Foundation Dinner in New York. "So I guess I'm the Meryl Streep of generals and frankly that sounds pretty good to me."
"And, you do have to admit, between me and Meryl, at least we've had some victories," he added.
Trump disparaged Mattis — who resigned as defense secretary last year — during a contentious White House meeting Wednesday with congressional Democratic leaders to discuss Trump's decision to pull US troops from Syria, according to a Democratic source familiar with the meeting.
Trump has previously leveled criticism at Streep, considered one of the best actors of her generation, just before taking office after she used an acceptance speech at the Golden Globes to criticize the then-President elect. Streep referenced Trump's mocking of a disabled New York Times reporter in her speech and said Trump used his position to "bully others."
The following day Trump called Streep "one of the most over-rated actresses in Hollywood" and referred to her as "a Hillary flunky who lost big."
During his speech on Thursday, Mattis insisted that Trump's comments didn't bother him. Mattis riffed that he "earned my spurs at the battlefield" while Trump "earned his spurs from a letter from the doctor" in a pointed jab at his former boss' cited reason for avoiding the Vietnam War draft.
Mattis went on to joke that "the only person on the military that Mr. Trump doesn't think is overrated" is "Colonel Sanders," the founder of the Kentucky Fried Chicken fast food restaurant chain.
Mattis resigned in December 2018 on the heels of Trump's announced plans to withdraw troops from Syria, citing irreconcilable policy differences in a move that took Washington by surprise at the time.
"Because you have the right to have a Secretary of Defense whose views are better aligned with yours on these and other subjects, I believe it is right for me to step down from my position," Mattis wrote in his letter to the President.
The former defense secretary's comments Thursday night come as Trump faces bipartisan criticism over his decision to withdraw US troops from Syria. On Wednesday, the House overwhelmingly passed a resolution opposing the Trump administration's troop withdrawal.
Earlier in the day, retired four-star Admiral William McRaven, the architect of the raid that killed Osama bin Laden, said Trump was working to "destroy" the country from "within" and "without."
FOX 2 News is Everywhere You Go!
Streaming TV, podcasts, FREE apps, social media and much more! Click HERE to CONNECT with FOX 2 News.
Trump insists 'All is well!' after Iran missile attack
Trump to address nation after Iran attacks Iraqi bases housing US troops in retaliation for Soleimani's death
Conservative radio host says his show was pulled because he criticized Trump
Amazon claims Trump interfered with Pentagon contract in order to hurt Jeff Bezos
Giuliani associate says he watched Trump fire the US ambassador to Ukraine
Trump says 'Iran appears to be standing down' following its retaliatory attacks against Iraqi bases housing US troops
Video appears to show world leaders gossiping about Trump
Trump adds Ken Starr and Alan Dershowitz to impeachment defense team
New Jersey Democrat outspoken against Trump impeachment expected to switch parties, source says
'It was no secret': Ambassador says quid pro quo came at 'express direction of the President'
Trump reiterates threat to target Iranian cultural sites
Trump administration reaches 100-mile mark for border wall
Despite president's claims, Saudi Arabia does not appear to have paid $1 billion to house US troops


text:
Elana Fine
Dingman Center for Entrepreneurship, University of Maryland
rhsmith.umd.edu/dingman
Elana Fine was appointed Managing Director of the Dingman Center in July 2012 after joining the team in 2010 as Director of Venture Investments. As Managing Director, Elana's primary focus is leading the Dingman Center in support of its mission and strategic plan. Elana also develops and maintains relationships with donors, board members, EIRs, the Smith School community and other campus and regional partners. Prior to joining the Dingman team, Elana was an Associate and a Vice-President at the Boston office of Revolution Partners, a national middle market investment bank specializing in mergers and acquisitions and private capital advisory for the technology industry. From 1997-2000, Elana was a consultant with Accenture, where she implemented technology solutions for clients in the financial services, government and natural resources industries.Elana earned an MBA in Finance and Accounting from the University of Chicago's Booth School of Business in 2002, and earned a BS in Finance, magna cum laude, from the Smith School of Business at the University of Maryland, College Park, in 1997.
Accelerator Showcase Artisphere


To formally "become" a Buddhist, the traditional way is to "take refuge" in the Three Jewels of Buddhism: the Buddha, the Dharma, and the Sangha. But even if you never identify as a Buddhist, there is much to gain and to learn by understanding the practice of taking refuge. Let's explore this ancient ritual and teaching, and see how it can support us on our individual paths of awakening to more light, wisdom, compassion and freedom.
All are welcome! Love Offering.